Dasatinib

Dasatinib
Clinical data
Trade names	Sprycel, Dasanix
AHFS/Drugs.com	Monograph
MedlinePlus	a607063
License data	EU EMA: by INN; US DailyMed: Dasatinib; US FDA: Dasatinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth (tablets)
ATC code	L01EA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	96%
Metabolism	Liver
Elimination half-life	1.3 to 5 hours
Excretion	Fecal (85%), kidney (4%)
Identifiers
	IUPAC name N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-; 1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole; carboxamide monohydrate;
CAS Number	302962-49-8 ;
PubChem CID	3062316;
IUPHAR/BPS	5678;
DrugBank	DB01254 ;
ChemSpider	2323020 ;
UNII	X78UG0A0RN;
KEGG	D03658 ;
ChEBI	CHEBI:49375 ;
ChEMBL	ChEMBL1421 ;
CompTox Dashboard (EPA)	DTXSID4040979 ;
ECHA InfoCard	100.228.321
Chemical and physical data
Formula	C22H26ClN7O2S
Molar mass	488.01 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl;
	InChI InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) ; Key:ZBNZXTGUTAYRHI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

Common adverse effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea. Severe adverse effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome. Use during pregnancy may result in harm to the baby. It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.

Dasatinib was approved for medical use in the United States and in the European Union in 2006. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.